Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 10/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20931160 | 0.90 | PIK3CA (0.43) | HDAC6HDAC8HDAC3HDAC1RIPK1 | |
| SCHEMBL17960094 | 0.86 | HDAC6 (0.57) | HDAC6HDAC8HDAC3HDAC1HPGD | |
| SCHEMBL17960232 | 0.84 | HDAC6 (0.47) | HDAC6HDAC8HDAC3HDAC1RIPK1 | |
| SCHEMBL17960511 | 0.84 | HDAC6 (0.58) | HDAC6HPGDRIPK1NPC1RAB9A | |
| SCHEMBL17960436 | 0.84 | HDAC6 (0.48) | HDAC6HDAC8HDAC3HDAC1HPGD | |
| SCHEMBL17960656 | 0.84 | HPGD (0.60) | HPGDNPC1RAB9AALDH1A1 | |
| SCHEMBL17960157 | 0.83 | HDAC6 (0.46) | HDAC6HDAC8HDAC3HDAC1RIPK1 | |
| SCHEMBL17960271 | 0.83 | GPR183 (0.52) | HDAC6HDAC8HDAC3HDAC1HPGD | |
| SCHEMBL17960198 | 0.82 | HDAC6 (0.47) | HDAC6HDAC8HDAC3HDAC1HPGD | |
| SCHEMBL17960461 | 0.82 | HDAC6 (0.52) | HDAC6HDAC8HDAC3HDAC1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160222028-A1 | 3-ALKYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | VALO HEALTH, INC. | 2016-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160222028-A1 | 3-ALKYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | HDAC1, HDAC4, HDAC2 | HDAC6 6/4885HDAC8 9/4885HDAC3 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.